Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060356 · ClinicalTrials.gov registry record · Early Phase 1
Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 77
- Enrollment target
NCT03060356: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT03060356 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 77 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060356, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET") in patients with advanced melanoma or breast carcinoma.
Interventions
- BIOLOGICAL T cells modified with RNA anti -cMET CAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-12-21 |
| Est. Completion | 2020-03-27 |
| Phase | Early Phase 1 |
Why NCT03060356 stopped before completion
NCT03060356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 1 intervention - of which T cells modified with RNA anti -cMET CAR is the first listed.
NCT03060356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03060356 about?
NCT03060356 is a clinical study titled "Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)". This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET")...
What is the current status of trial NCT03060356?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 77 participants. The study started on 2016-12-21. Estimated completion is 2020-03-27.
What interventions are being tested in trial NCT03060356?
The interventions under investigation include: T cells modified with RNA anti -cMET CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT03060356?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03060356's enrollment target sits among peer trials
77 302nd of 2000 higher than 1,698 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI